H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Antares Pharma (NASDAQ: ATRS) today and set a price target of $4. The company’s shares opened today at $2.25.
Livnat said:
“Exchange NASDAQ Value (M) $373.2 Market Cap (M) $370 Shares Outstanding (M) 156.8 3 Interest (M) 6.41 Cash (M) $21.8 Total Debt (M) $25.0 Year – (0.04)A — 2Q (0.02) (0.04) — 3Q (0.03) (0.02) — 4Q (0.02) (0.01) — FY (0.11) (0.11) 0.04 Year – 12.7A — 2Q 13.4 12.4 — 3Q 15.1 17.0 — 4Q 14.0 18.7 — FY 54.5 60.8 117.3 4.5 4 3.5 3 2.5 2 1.5 0 Vol. (mil) Price Increased confidence in Xyosted 2018 Approval.”
According to TipRanks.com, Livnat is ranked 0 out of 5 stars with an average return of -10.5% and a 29.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Antares Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $3.68.
See today’s analyst top recommended stocks >>
Based on Antares Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.71 million. In comparison, last year the company had a GAAP net loss of $4.74 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATRS in relation to earlier this year. Earlier this month, Jacques Gonella, a Director at ATRS bought 30,000 shares for a total of $25,500.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Antares Pharma, Inc. is a pharmaceutical company. The company focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its activities include the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.
